# From Metabolism to Mind: The Cardio–Metabolic–Brain Axis and the Role of Insulin Resistance—A Review

**Authors:** Joanna Cielecka, Zuzanna Szkamruk, Maciej Walędziak, Anna Różańska-Walędziak

PMC · DOI: 10.3390/biomedicines14020394 · Biomedicines · 2026-02-09

## TL;DR

This review explores how insulin resistance connects metabolic and cardiovascular issues with brain health, suggesting it plays a key role in cognitive decline and Alzheimer's disease.

## Contribution

The paper introduces the cardio–metabolic–brain axis as a novel integrative model linking insulin resistance to metabolic, cardiovascular, and neurodegenerative processes.

## Key findings

- Insulin resistance contributes to endothelial dysfunction, chronic inflammation, and oxidative stress, promoting atherosclerosis and neurodegeneration.
- Individuals with elevated insulin resistance show higher risks of cardiovascular events and cognitive decline, regardless of diabetes status.
- Brain insulin resistance impairs glucose utilization and facilitates amyloid accumulation, similar to mechanisms in Alzheimer’s disease.

## Abstract

(1) Background: Insulin resistance (IR) is increasingly recognized not only as a key factor in metabolic and cardiovascular disorders but also as an important contributor to cognitive decline. The growing prevalence of obesity, type 2 diabetes mellitus, and cardiovascular disease (CVD), paralleled by rising rates of dementia, highlights the need for an integrative model linking these conditions. The emerging cardio–metabolic–brain axis proposes a unified model explaining how biomarkers of metabolic stress, adipose-tissue-derived mediators, and abnormalities in laboratory parameters interact with vascular injury and neurodegeneration. (2) Methods: A comprehensive literature review was conducted using MEDLINE, SCOPUS, and Web of Science databases, complemented by additional searches in Embase and Cochrane Library. Studies from the past decade were screened using keywords such as “insulin resistance”, “cardio-metabolic-brain axis”, “cognitive decline”, and “cardiovascular disease”. Both epidemiological and mechanistic studies were analyzed to summarize current evidence and identify research gaps. (3) Results and Conclusions: Evidence indicates that insulin resistance contributes to endothelial dysfunction, chronic inflammation, and oxidative stress, driving the metabolic abnormalities characteristic of obesity and type 2 diabetes and promoting both atherosclerosis and neurodegeneration. Individuals with elevated IR—regardless of diabetes status—display higher risks of cardiovascular events and measurable cognitive decline. Brain insulin resistance further impairs glucose utilization, disrupts synaptic function, and facilitates amyloid accumulation, reflecting mechanisms observed in Alzheimer’s disease. These findings support IR as a key biomarker linking metabolic stress, vascular injury, and neural vulnerability within the cardio–metabolic–brain axis. Early identification of IR, together with targeted lifestyle and pharmacological interventions, may therefore offer dual benefits for cardiovascular and brain health. Continued longitudinal research is needed to validate this integrative model and refine therapeutic strategies aimed at improving insulin sensitivity.

## Linked entities

- **Diseases:** obesity (MONDO:0011122), type 2 diabetes mellitus (MONDO:0005148), cardiovascular disease (MONDO:0004995), dementia (MONDO:0001627), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ITLN1 (intelectin 1) [NCBI Gene 55600] {aka HL-1, HL1, INTL, ITLN, LFR, hIntL}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}
- **Diseases:** neurocognitive deterioration (MESH:D019965), neural dysfunction (MESH:D015441), white (MESH:D000090122), neurotoxic (MESH:D020258), Cardiovascular Disease (MESH:D002318), non-alcoholic fatty liver disease (MESH:D065626), impaired glucose uptake (MESH:C536778), myocardial infarction (MESH:D009203), MCI (MESH:D060825), AD (MESH:D000544), cerebral circulation (MESH:D020520), deficits in memory, attention and processing speed (MESH:D001289), end-organ damage (MESH:C564816), hypertrophy (MESH:D006984), diabetes (MESH:D003920), Endothelial dysfunction (MESH:D014652), ischemic injury (MESH:D017202), liver fibrosis (MESH:D008103), prediabetes (MESH:D011236), weight loss (MESH:D015431), Type 3 Diabetes (MESH:C566342), subcortical vascular injury (MESH:D057772), metabolic and vascular dysfunction (MESH:D002561), BBB dysfunction (MESH:C536830), overnutrition (MESH:D044343), Impaired brain glucose metabolism (MESH:D044882), Neuroinflammation (MESH:D000090862), BIR (MESH:D007333), atrophy (MESH:D001284), proteinopathy (MESH:D057165), inflammation (MESH:D007249), cardiovascular and neurodegenerative disease (MESH:D019636), disease (MESH:D004194), injury to (MESH:D014947), cardiometabolic abnormalities (MESH:D024821), thrombotic (MESH:D013927), Hyperglycemia (MESH:D006943), microvascular dysfunction (MESH:D017566), fibrosis (MESH:D005355), impaired cerebral perfusion (MESH:D002547), CV death (MESH:D003643), Dyslipidemia (MESH:D050171), impaired glucose regulation (MESH:C565631), hyperinsulinemic-euglycemic (MESH:D044903), Hyperinsulinemia (MESH:D006946), hypertension (MESH:D006973), brain dysfunction (MESH:D001927), vascular and neural impairment (MESH:D020141), brain injury (MESH:D001930), diabetic cardiomyopathy (MESH:D058065), coordination (MESH:D001259), arterial stiffness (MESH:C566112), mitochondrial dysfunction (MESH:D028361), disturbances (MESH:D014832), impaired cerebral blood flow (MESH:D054318), atherogenesis (MESH:D050197), Metabolic Dysfunction (MESH:D008659), glucose intolerance (MESH:D018149), cerebral microangiopathy (MESH:D059345), ischemia (MESH:D007511)
- **Chemicals:** aldosterone (MESH:D000450), triglyceride (MESH:D014280), FDG (MESH:D019788), fatty acid (MESH:D005227), Ca2+ (-), superoxide anions (MESH:D013481), TG (MESH:D013866), sugar (MESH:D000073893), oxygen (MESH:D010100), sodium (MESH:D012964), glutamate (MESH:D018698), diacylglycerols (MESH:D004075), NO (MESH:D009569), Cholesterol (MESH:D002784), Glucose (MESH:D005947), ceramide (MESH:D002518), calcium (MESH:D002118), ROS (MESH:D017382), ATP (MESH:D000255), phospholipid (MESH:D010743), methylglyoxal (MESH:D011765), AGEs (MESH:D017127), peroxynitrite (MESH:D030421), thiazolidinediones (MESH:D045162), Metformin (MESH:D008687), lipid (MESH:D008055), FFAs (MESH:D005230)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937805/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937805/full.md

## References

146 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937805/full.md

---
Source: https://tomesphere.com/paper/PMC12937805